Congressional feedback on PhRMA annual meeting
Executive Summary
Rep. Donna Christensen (D-V.I.) had a "very good discussion" with PhRMA at the group's recent annual meeting, she tells an Alliance of Minority Medical Associations conference in Washington, D.C. April 19. "It was a very frank and open discussion about the need to ensure that patients got the best medication for their particular illness or disease," Christensen said. "Despite often having differences of opinion, we consider the pharmaceutical industry our partners in providing health care." Christensen participated in a panel discussion on access to medicines at PhRMA (1"The Pink Sheet" April 12, 2004, p. 12)...
You may also be interested in...
PhRMA On The “Defensive”: Sen. Breaux Notes Criticism Is Bipartisan
The brand name pharmaceutical industry must recognize that it is a convenient political target for members of Congress in both parties, Sen. John Breaux (D-La.) warned the Pharmaceutical Research & Manufacturers of America during the association's annual meeting April 3 in Palm Beach, Fla
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.